logo
Plus   Neg
Share
Email

Lilly Reports Positive Results From Taltz 5-yr Study - Quick Facts

Eli Lilly and Company (LLY) said the results from a five-year Phase 3 study for Taltz (ixekizumab) demonstrated that patients with moderate- to severe plaque psoriasis taking Taltz can achieve sustained skin clearance over the five-year treatment period. No unexpected safety outcomes were reported, the company said.

Later in the year, Eli Lilly plans to announce the results from IXORA-R, a clinical trial designed to evaluate superiority between Taltz and Tremfya (guselkumab) in adult patients with moderate- to severe plaque psoriasis.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Online-video streaming giant Netflix Inc. (NFLX), Tuesday reported a fourth-quarter profit that trounced Wall Street estimates, as revenues surged 31% driven by strong subscriber growth. Netflix added 8.76 million subscribers globally in the quarter, above its forecast of 7.60 million, to end the... Fast food chain Krystal Company has filed for bankruptcy, according to reports. The Atlanta-based Krystal filed for Chapter 11 on Sunday in the U.S. Bankruptcy Court in Atlanta. In the filing, the company reportedly disclosed assets between $10 million and $50 million, and liabilities between $50 million and $100 million. The chief executive officer of Google's parent company Alphabet called for artificial intelligence or AI to be regulated, noting that there are real concerns about the potential negative consequences of the technology. According to Alphabet CEO Sundar Pichai, there are real concerns about the negative consequences of AI, from deepfakes to nefarious uses of facial recognition.
Follow RTT
>